MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.14 (35.65% upside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016RBC CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Cowen and CompanyReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016William BlairReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016BarclaysReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016JPMorgan Chase & Co.Reiterated RatingOutperform$11.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/11/2014Credit SuisseDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Citigroup Inc.Reiterated RatingSell$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.02$0.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20162($0.22)($0.19)($0.21)
Q4 20162($0.18)($0.11)($0.15)
(Data provided by Zacks Investment Research)
Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline
06/27/16 02:52 PMNDA Submission Initiated for Brigatinib in ALK+ Non-small Cell Lung Cancer
06/27/16 02:52 PMBedford man rides for a cause
06/27/16 07:18 AMuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications
06/24/16 08:26 AMAriad Pharmaceuticals : Announces Webcast of Its Annual Stockholders Meeting
06/24/16 06:35 AMARIAD Announces Webcast of Its Annual Stockholders Meeting - [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced that its Annual Meeting of Stockholders will be webcast live on July 21, 2016 and can be accessed by visiting the investor relations section of the Company’s website at: http://www.ariad.com/investor.
06/23/16 09:59 PMWorth Watching Intraday Movers: MGT Capital Investments Inc. (NYSEMKT:MGT), Ariad Pharmaceuticals, Inc ... - NYSE Journal (press release)
06/23/16 04:03 PMAriad Pharmaceuticals Inc. versus Arena Pharmaceuticals, Inc. Head to Head Compare - CML News
06/22/16 02:35 PMTrending Stock Analysis: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - News Oracle
06/22/16 07:20 AMMost recent Analysts Rating report: Boston Scientific Corporation (NYSE:BSX) , ARIAD Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/21/16 10:21 AMARIAD Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARIA) : June 21, 2016 -
06/21/16 07:20 AMStrong Buy Calls Count For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) At 3 - Investor Newswire
06/21/16 07:20 AMHC Stocks Broker Alerts: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release)
06/21/16 07:20 AMAnalyst's Noticeable Buzzers: Mast Therapeutics, Inc. (NYSEMKT:MSTX) , ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Street Updates
06/20/16 02:33 PMAriad Taking The Fast Track Into Lung Cancer Treatment - Seeking Alpha
06/20/16 02:33 PMAriad Pharmaceuticals Inc. Stock Momentum Hits Strength - CML News
06/20/16 02:33 PMAnalysts Reiterate Buy on Cerus Corporation (CERS) and Ariad Pharmaceuticals, Inc. (ARIA) Following Agreement ... - Smarter Analyst
06/20/16 09:02 AMARIAD inks distribution deals for Iclusig in Latin America, Middle East/North Africa
06/20/16 07:33 AMARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARIA-US : June 20, 2016 -
06/19/16 07:18 AMARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 07:19 AMAriad Pharmaceuticals Inc. Stock Momentum Hits Weakness - CML News
06/17/16 02:33 PMCompany Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Initiates Submission of New Drug Application for ... - Smarter Analyst
06/17/16 01:36 PMBRIEF-Ariad Pharmaceuticals completes strategic review, reaffirms 2016 outlook - * Outcomes of strategic review includes significant reduction in company's expense base
06/17/16 11:33 AMARIAD Completes Strategic Review and Announces Plans for Growth - [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced the completion of its strategic review and its plans for future growth and vision to become a leader in the discovery, development and commercialization of precision therapies for patients with rare cancers.
06/17/16 09:56 AMWhy Mosaic, Vale, and Three Other Stocks Are in the Spotlight -
06/17/16 06:45 AMARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa - [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced that it has completed two distribution agreements for Iclusig® outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize Iclusig in Argentina, ...
06/16/16 02:35 PMEarnings Estimates Review: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - News Oracle
06/16/16 02:35 PMEarnings Estimates Review: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - News Oracle
06/16/16 02:35 PMEarnings Analysis to Watch: Weibo Corporation (NASDAQ:WB), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Beacon Chronicle
06/16/16 02:35 PMEarnings Analysis to Watch: Weibo Corporation (NASDAQ:WB), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Beacon Chronicle
06/15/16 07:23 AMEarnings Analysis to Watch: Welltower Inc. (NYSE:HCN), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Beacon Chronicle
06/15/16 07:23 AMAnalysts Actions to Track: Opko Health Inc (NYSE:OPK) , ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Street Updates
06/14/16 02:34 PMAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) Updates On Phase 2 Study Of Ponatinib - Market Exclusive
06/13/16 10:39 AMAnalyst Overview on these Stocks: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Himax Technologies, Inc. (NASDAQ ... - Beacon Chronicle
06/13/16 09:46 AMAriad Reveals Ponatinib's Long-Term Safety And Efficacy Data From Stage 2 Clinical Study -
06/10/16 02:38 PMNotable Analyst's Ranking Preview: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Brookdale Senior Living Inc ... - Street Updates
06/10/16 02:38 PMEarnings Overview: United Continental Holdings, Inc. (NYSE:UAL), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Beacon Chronicle
06/09/16 08:28 PM3 Reasons Ariad Pharmaceuticals Inc. Stock Rose 23.3% in May - Motley Fool
06/09/16 02:34 PMAriad Pharmaceuticals Inc. (NASDAQ:ARIA) Fundamental Star Rating Report - CML News
06/09/16 11:29 AMAnalyst Suggestions Roundup: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), CBS Corporation (NYSE:CBS) - Beacon Chronicle
06/08/16 08:57 PMAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q - Market Exclusive
06/08/16 05:51 PMAriad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q -
06/08/16 11:02 AMTwo Stocks within Analysts Review: Boston Scientific Corporation (NYSE:BSX) , ARIAD Pharmaceuticals, Inc ... - Street Updates
06/07/16 08:09 PMToday's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA) - TheStreet.com
06/07/16 03:09 PMARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/07/16 02:37 PMKeep an eye on Analyst Actions: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Juno Therapeutics, Inc. (NASDAQ ... - Street Updates
06/07/16 02:37 PMAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) & Exelixis, Inc. (NASDAQ:EXEL) Healthcare Notable Runners - Wall Street 24
06/07/16 11:00 AMARIAD (ARIA) Presents Phase II Study Data on Cancer Drug -
06/07/16 10:32 AMHC Stocks Judgment: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY) - share market updates (press release)
06/07/16 10:32 AMBuy Sell or Hold? - Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), AK Steel Holding Corporation (NYSE:AKS) - Beacon Chronicle
06/06/16 07:46 PMARIAD PHARMACEUTICALS INC. (NASDAQ:ARIA) Financial Condition Compared to S&P 500 - CML News
About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $7.18
  • 50 Day Moving Average: $7.96
  • 200 Day Moving Average: $6.53
  • P/E Ratio: N/A
  • P/E Growth: -0.42
  • Market Cap: $1.29B
  • Current Quarter EPS Consensus Estimate: $-0.60 EPS
Additional Links:
Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha